TNXP Tonix Pharmaceuticals Holding Corp.

4.15
-0.10  -2%
Previous Close 4.25
Open 4.27
Price To book 0.92
Market Cap 31160943
Shares 7,508,661
Volume 51,760
Short Ratio 3.22
Av. Daily Volume 108,833

SEC filingsSee all SEC filings

  1. RW - Registration Withdrawal Request 171088667
  2. 8-K - Current report 171085759
  3. 8-K - Current report 171084589
  4. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 171066946
  5. 8-K - Current report 171058344

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initiation of first of two Phase 3 trials announced March 28, 2017 in military-related PTSD 1Q 2017. Interim analysis due 1H 2018 with top-line data due 2H 2018.
TNX-102 SL
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
TNX-201
Episodic tension-type headache
Phase 3 data released September 6, 2016. Primary endpoint not met. Program discontinued
TNX-102 SL
Fibromyalgia

Latest News

  1. Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
  2. Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors
  3. Corporate News Blog - Eli Lilly's Galcanezumab Treatment Shows Positive Safety Results in the 12-Month Phase-3 Study
  4. Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  5. Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
  6. Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium
  7. TNXP: Patient Enrollment Continues for Phase 3 Study of Tonmya® in PTSD; Interim Analysis Expected in 1H18
  8. Tonix reports 2Q loss
  9. Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update
  10. Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
  11. Corporate News Blog - Lilly Announces Galcanezumab Results Presented at AHS; Reported Reduced Number of Migraine Headache Days for Patients with Acute Migraine
  12. Today's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Calithera Biosciences
  13. TNXP: Interim Analysis for HONOR Study Expected in 1H18

SEC Filings

  1. RW - Registration Withdrawal Request 171088667
  2. 8-K - Current report 171085759
  3. 8-K - Current report 171084589
  4. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 171066946
  5. 8-K - Current report 171058344
  6. 8-K - Current report 171026832
  7. S-3 - Registration statement under Securities Act of 1933 171025782
  8. S-8 - Securities to be offered to employees in employee benefit plans 171025627
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171025540
  10. 8-K - Current report 17997157